发布求助
文献互助 智能选刊 最新文献

Clinical and Experimental Ophthalmology最新文献

筛选
英文 中文
Genotype-Phenotype Correlations in Corneal Dystrophies: Advances in Molecular Genetics and Therapeutic Insights.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-13 DOI: 10.1111/ceo.14516
Petra Liskova, Pavlina Skalicka, Lubica Dudakova, Andrea L Vincent
{"title":"Genotype-Phenotype Correlations in Corneal Dystrophies: Advances in Molecular Genetics and Therapeutic Insights.","authors":"Petra Liskova, Pavlina Skalicka, Lubica Dudakova, Andrea L Vincent","doi":"10.1111/ceo.14516","DOIUrl":"https://doi.org/10.1111/ceo.14516","url":null,"abstract":"<p><p>Corneal dystrophies are a group of predominantly rare inherited disorders. They are by definition bilateral, relatively symmetrical, and without systemic involvement, affecting corneal transparency and/or refraction. Traditional classification of corneal dystrophies is based on slit-lamp appearance, affected corneal layer and histological features. Molecular genetics has provided ultimate proof for the existence of distinct corneal dystrophies and discarded duplicates in their terminology. Currently, there are at least 16 genes with identified pathogenic variants implicated in corneal dystrophies. Herein, we summarise contemporary knowledge on genotype-phenotype correlations of corneal dystrophies, including a critical review of some reported variants, along with the understanding of the underlying pathogenic dystrophic process; essential knowledge for the development of targeted therapies.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Longitudinal Retinal Changes in Health and Disease: Response.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-12 DOI: 10.1111/ceo.14519
Zhi Da Soh, Ching-Yu Cheng
{"title":"Rethinking Longitudinal Retinal Changes in Health and Disease: Response.","authors":"Zhi Da Soh, Ching-Yu Cheng","doi":"10.1111/ceo.14519","DOIUrl":"https://doi.org/10.1111/ceo.14519","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Dorzolamide for Macular Holes: A Randomised, Double-Blind, Placebo-Controlled Trial-Comment.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-12 DOI: 10.1111/ceo.14521
Nicolas Abihaidar, Nacim Bouheraoua, Vincent Borderie, Thibaud Garcin
{"title":"Topical Dorzolamide for Macular Holes: A Randomised, Double-Blind, Placebo-Controlled Trial-Comment.","authors":"Nicolas Abihaidar, Nacim Bouheraoua, Vincent Borderie, Thibaud Garcin","doi":"10.1111/ceo.14521","DOIUrl":"https://doi.org/10.1111/ceo.14521","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-08 DOI: 10.1111/ceo.14514
Ngozi C Chidi-Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L Watson
{"title":"Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.","authors":"Ngozi C Chidi-Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L Watson","doi":"10.1111/ceo.14514","DOIUrl":"https://doi.org/10.1111/ceo.14514","url":null,"abstract":"<p><strong>Background: </strong>To identify evidence on the use of topical CsA for ocular surface diseases (OSD).</p><p><strong>Methods: </strong>A literature search was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching. Randomised clinical trials (RCTs) in which different concentrations of topical CsA were compared with one another or other topical therapies were included. Risk of bias was assessed following the Cochrane ROB2 standard tool. Meta-analysis was considered when data were sufficient. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE).</p><p><strong>Results: </strong>Five hundred and eight-three RCT publication titles were identified, of which 48 OSD RCTs were included. Thirty trials found significantly better efficacy with CsA irrespective of dose or concentration for OSD. The effect of CsA was comparable to artificial tears (AT), vehicle, fluorometholone 0.1%, tacrolimus 0.03% or diquafosol 3% only in 13 trials. Improved outcomes with CsA for symptoms (RCTs comprising 1107-patients) and clinical signs, including in ocular surface staining (2505-patients) and the average number of goblet cells (138-patients) were found. Inconsistency of treatment effect on symptoms and signs, particularly tear film function, was evident in some trials. Ten trials were judged to be at high risk of bias. The certainty of evidence was judged to be low to moderate, downgraded mostly for imprecision and risk of bias.</p><p><strong>Conclusions: </strong>Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Longitudinal Retinal Changes in Health and Disease.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-07 DOI: 10.1111/ceo.14520
Guanghao Qin
{"title":"Rethinking Longitudinal Retinal Changes in Health and Disease.","authors":"Guanghao Qin","doi":"10.1111/ceo.14520","DOIUrl":"https://doi.org/10.1111/ceo.14520","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of an Intravitreal Bevacizumab Biosimilar (MVASI). 玻璃体内贝伐珠单抗生物仿制药（MVASI）的安全性。
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-05 DOI: 10.1111/ceo.14515
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little
{"title":"Safety of an Intravitreal Bevacizumab Biosimilar (MVASI).","authors":"Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little","doi":"10.1111/ceo.14515","DOIUrl":"https://doi.org/10.1111/ceo.14515","url":null,"abstract":"<p><strong>Background: </strong>Intravitreal bevacizumab has been used off-label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020. There is limited safety data for the off-label intravitreal use of MVASI. This retrospective study evaluates the safety of intravitreal MVASI.</p><p><strong>Methods: </strong>Retrospective review of all eyes that were given intravitreal MVASI at all metropolitan public hospitals in South Australia between 1st May 2022 and 30th May 2024. Demographic data, injection indications, number of injections per eye, whether patients were switched to another agent, and associated complications were collected from electronic and paper medical records.</p><p><strong>Results: </strong>A total of 6230 injections were given to 1682 eyes in this study. The mean age of the study population was 69.8 ± 15.6 years. The overall mean number of MVASI injections given per eye was 3.7 ± 2.9 (range 1-21). The indications for treatment were neovascular age-related macular degeneration (2106 injections; 33.8%), diabetic macular oedema (1634 injections; 26.2%), branch retinal vein occlusion (695 injections; 11.2%), proliferative diabetic retinopathy (596 injections; 9.6%), central retinal vein occlusion (558 injections; 9.0%) and other (641 injections; 10.3%). Significant sight-threatening complications included 3 cases of bacterial endophthalmitis (0.05%) and 3 cases of uveitis (0.05%). No cases of retinal vasculitis were observed.</p><p><strong>Conclusions: </strong>Intravitreal MVASI had a similar ophthalmic safety profile and may be used as an alternative to Avastin.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cataract Surgery in the Small Adult Eye: A Review.
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-04 DOI: 10.1111/ceo.14510
Jonathan E Moore, Richard N McNeely, Salissou Moutari
{"title":"Cataract Surgery in the Small Adult Eye: A Review.","authors":"Jonathan E Moore, Richard N McNeely, Salissou Moutari","doi":"10.1111/ceo.14510","DOIUrl":"https://doi.org/10.1111/ceo.14510","url":null,"abstract":"<p><p>Modern cataract surgery continues to advance, yet intraocular lens (IOL) based surgery in the small adult eye remains challenging. Thorough preoperative assessment and surgical preparation optimise postoperative outcomes in these cases. Advances in IOL power calculation, including artificial intelligence-driven formulas, improve accuracy; however, careful consideration of biometry and IOL power selection is still necessary because inaccuracies can produce significant errors. Limited availability of high-powered IOLs to fully correct high refractive errors may necessitate further intervention. Surgical techniques have evolved to address the unique anatomical challenges of small eyes, improving safety and outcomes. Knowledge of the potential risks inherent in these cases can assist the surgeon in modifying the operative technique accordingly. This review discusses essential preoperative assessments, IOL power selection, surgical techniques, and potential complications, offering guidance for surgeons performing cataract surgery on small adult eyes.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uveal Melanoma Treatment: A Paradigm Shift?
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-03 DOI: 10.1111/ceo.14496
Gustav Stålhammar
{"title":"Uveal Melanoma Treatment: A Paradigm Shift?","authors":"Gustav Stålhammar","doi":"10.1111/ceo.14496","DOIUrl":"https://doi.org/10.1111/ceo.14496","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 2","pages":"113-115"},"PeriodicalIF":4.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuing Professional Development
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-03 DOI: 10.1111/ceo.14499
{"title":"Continuing Professional Development","authors":"","doi":"10.1111/ceo.14499","DOIUrl":"https://doi.org/10.1111/ceo.14499","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 2","pages":"221-224"},"PeriodicalIF":4.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Challenge of Managing Paediatric Periorbital Cellulitis
IF 4.9 2区 医学
Clinical and Experimental Ophthalmology Pub Date : 2025-03-03 DOI: 10.1111/ceo.14497
Kathy Jao, Shuan Dai
{"title":"The Challenge of Managing Paediatric Periorbital Cellulitis","authors":"Kathy Jao,&nbsp;Shuan Dai","doi":"10.1111/ceo.14497","DOIUrl":"https://doi.org/10.1111/ceo.14497","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 2","pages":"116-118"},"PeriodicalIF":4.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信